Premium
Levocarnitine Decreases Intradialytic Hypotension Episodes: A Randomized Controlled Trial
Author(s) -
IbarraSifuentes Héctor Raúl,
Del CuetoAguilera Ángel,
GallegosArguijo Daniel Alberto,
CastilloTorres Sergio Andres,
VeraPineda Raymundo,
MartínezGranados Rolando Jacob,
AtilanoDíaz Alexandro,
CuellarMonterrubio Jesus Eduardo,
PezinaCantú Cesar Octaviano,
MartínezGuevara Edgar de Jesús,
OrtizTreviño Juan Francisco,
DelgadoGarcía Guillermo Rubén,
MartínezJiménez José Guadalupe,
CruzValdez Jesús,
SánchezMartínez Concepción
Publication year - 2017
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12553
Subject(s) - medicine , levocarnitine , hemodialysis , placebo , randomized controlled trial , incidence (geometry) , anesthesia , carnitine , alternative medicine , physics , pathology , optics
Intradialytic hypotension is common complication in stage 5 chronic kidney disease patients on hemodialysis. Incidence ranges from 15 to 30%. These patients have levocarnitine deficiency. A randomized, placebo‐controlled quadruple‐blinded trial was designed to demonstrate the levocarnitine efficiency on intradialytic hypotension prevention. Patients were randomized into four groups, to receive levocarnitine or placebo. During the intervention period, levocarnitine and placebo was administered 0 and 30 min before each hemodialysis session, respectively. During the trial, 33 patients received 1188 hemodialysis sessions. We identified 239 (21.3%) intradialytic hypotension episodes. The intradialytic hypotension episodes were less frequent in the levocarnitine group (9.3%, 60 IH events) ( P < 0.001). Hemodialysis is frequently perplexed by intradialytic hypotension episodes. Levocarnitine supplementation before each hemodialysis session efficiently diminishes the intradialytic hypotension episodes. This is a new application method that must be considered and explored.